Objectives: This study explores factors associated with differential awareness of genetic tests for increased cancer risk in the US. Methods: 27,405 respondents from the 2000 National Health Interview Survey, ages 25+, were asked if they had heard of these tests. Results: 44.4% said ‘yes’, including 49.9% of whites, 32.9% of African-Americans, 32.3% of American Indians/Alaskan Natives, 28.0% of Asian/Pacific Islanders, and 20.6% of Hispanics. In multivariate analysis, test awareness was significantly associated with higher education, white race, age <60 years, female gender, private health insurance, personal or parent’s history of certain cancers, physical activity, and vitamin/supplement use, among other factors. Conclusions: The survey showed which population subgroups may lack access to cancer genetics information and may therefore benefit from targeted strategies to ensure risk-appropriate utilization of genetic counseling and testing.

Keywords:
Health survey, Genetic testing, Neoplasm, Cancer risk, Health disparity, Awareness
1.
Easton D, Peto J: The contribution of inherited predisposition to cancer incidence. Cancer Surv 1990;9:395–416.
2.
Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318–2324.
3.
Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review. Gastroenterology 1993;104:1535–1549.
4.
American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996;14:1730–1736;discussion 1737–1740.
5.
American Society of Human Genetics: Genetic testing for colon cancer: Joint statement of the American College of Medical Genetics and American Society of Human Genetics. Joint Test and Technology Transfer Committee Working Group. Genet Med 2000;2:362–366.
6.
American Gastroenterological Association: American Gastroenterological Association medical position statement: Hereditary colorectal cancer and genetic testing. Gastroenterology 2001;121:195–197.
7.
National Comprehensive Cancer Network. Genetic/Familial High-Risk Screening. Practice Guidelines in Oncology, version 1, 2001.
8.
New York State Department of Heath: Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling and Testing Guidelines: New York State Department of Health, 1999.
9.
Collaborative Group on Hormonal Factors in Breast Cancer: Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389–1399.
10.
Lindor NM, Greene MH: The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998;90:1039–1071.
11.
Ramsey SD, Freedman AN, Berry K, Andersen MR, Urban N: Prevalence of pedigrees suggestive of HNPCC among a community sample of eligible women for screening mammography. Community Genet 1999;2:172–178.
12.
Anton-Culver H, Kurosaki T, Taylor TH, Gildea M, Brunner D, Bringman D: Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry. Genet Epidemiol 1996;13:193–205.
13.
Anton-Culver H, Cohen PF, Gildea ME, Ziogas A: Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000;36:1200–1208.
14.
Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M, et al: The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001;121:830–838.
15.
Yoon PW, Chen B, Faucett A, Clyne M, Gwinn M, Lubin IM, Burke W, Khoury MJ: Public health impact of genetic tests at the end of the 20th century. Genet Med 2001;3:405–410.
16.
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 1999;64:963–970.
17.
Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–1487.
18.
Gao Q, Tomlinson G, Das S, Cummings S, Sveen L, Fackenthal J, Schumm P, Olopade OI: Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2000;107:186–191.
19.
Neuhausen SL: Ethnic differences in cancer risk resulting from genetic variation. Cancer 1999;86:2575–2582.
20.
Shtoyerman-Chen R, Friedman E, Figer A, Carmel M, Patael Y, Rath P, Fidder HH, Bar-Meir S, Theodor L: The I1307K APC polymorphism: Prevalence in non-Ashkenazi Jews and evidence for a founder effect. Genet Test 2001;5:141–146.
21.
Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrjakoski I, Kainu T, Vahteristo P, Krahe R, Paakonen K, Hartikainen J, Blomqvist C, Lopponen T, Holli K, Ryynanen M, Butzow R, Borg A, Wasteson Arver B, Holmberg E, Mannermaa A, Kere J, Kallioniemi OP, Winqvist R, Nevanlinna H: Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet 2000;8:757–763.
22.
Rouba A, Kaisi N, Al-Chaty E, Badin R, Pals G, Young C, Worsham MJ: Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer. Int J Mol Med 2000;6:565–569.
23.
Arason A, Jonasdottir A, Barkardottir RB, Bergthorsson JT, Teare MD, Easton DF, Egilsson V: A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: Two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet 1998;35:446–449.
24.
Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K: Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther 2002;1:18–21; discussion 22–23.
25.
Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA: Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 2002;71:595–606.
26.
Lynch HT, Drouhard TJ, Schuelke GS, Biscone KA, Lynch JF, Danes BS: Hereditary nonpolyposis colorectal cancer in a Navajo Indian family. Cancer Genet Cytogenet 1985;15:209–213.
27.
Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975–978.
28.
Weber TK, Chin HM, Rodriguez-Bigas M, Keitz B, Gilligan R, O’Malley L, Urf E, Diba N, Pazik J, Petrelli NJ: Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer. JAMA 1999;281:2316–2320.
29.
Furukawa T, Konishi F, Shitoh K, Kojima M, Nagai H, Tsukamoto T: Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma. Cancer 2002;94:911–920.
30.
Panguluri RC, Brody LC, Modali R, Utley K, Adams-Campbell L, Day AA, Whitfield-Broome C, Dunston GM: BRCA1 mutations in African Americans. Hum Genet 1999;105:28–31.
31.
Bar-Sade RB, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, Theodor L, Novikov I, Gershoni-Baruch R, Risel S, Pap MZ, Ben-Baruch G, Friedman E: The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim. Hum Mol Genet 1998;7:801–805.
32.
Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC: Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915–921.
33.
Arena JF, Smith S, Vineck V, Gayol L, Villegas F, Perera E: A BRCA1 founder mutation in African-Americans. Am J Hum Genet Suppl 1997;61:A14.
34.
Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI: Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet 1997;60:1233–1236.
35.
Peelen T, Van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, Van den Ouweland AM, Hogervorst, F, Brohet R, Ligtenberg MJ, Teugels E, Van der Luijt R, Van der Hout AH, Gillev J, Pals G, Jedema I, Olmer R, Van Leeuwen I, Newman B, Plandsoen M, Van der Est M, Brink G, Hageman S, Arts PJ, Bakker MM, Devilee P: A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997;60:1041–1049.
36.
Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Streuwing J, Tonin P, Durocher F, Narad S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE: Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study. Am J Hum Genet 1996;58:271–280.
37.
Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC: Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284–1297.
38.
Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Belanger C, Dion F: Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392–398.
39.
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, Fourquet A, Salmon RJ, Cough KB, Pouillart P, Bonaiti-Pellie C, Thomas G: BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 1997;60:1021–1030.
40.
Petersen GM, Brensinger JD, Johnson KA, Giardiello FM: Genetic testing and counseling for hereditary forms of colorectal cancer. Cancer 1999;86:2540–2550.
41.
Schwartz MD, Benkendorf J, Lerman C, Isaacs C, Ryan-Robertson A, Johnson L: Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: Testing among Ashkenazi Jewish women. Cancer 2001;92:932–940.
42.
Mogilner A, Otten M, Cunningham JD, Brower ST: Awareness and attitudes concerning BRCA gene testing. Ann Surg Oncol 1998;5:607–612.
43.
Meischke H, Bowen DJ, Kuniyuk A: Awareness of genetic testing for breast cancer risk among women with a family history of breast cancer: Effect of women’s information sources on their awareness. Cancer Detect Prev 2001;25:319–327.
44.
Tambor ES, Rimer BK, Strigo TS: Genetic testing for breast cancer susceptibility: Awareness and interest among women in the general population. Am J Med Genet 1997;68:43–49.
45.
Mouchawar J, Byers T, Cutter G, Dignan M, Michael S: A study of the relationship between family history of breast cancer and knowledge of breast cancer genetic testing prerequisites. Cancer Detect Prev 1999;23:22–30.
46.
Bosompra K, Flynn BS, Ashikaga T, Rairikar CJ, Worden JK, Solomon LJ: Likelihood of undergoing genetic testing for cancer risk: A population-based study. Prev Med 2000;30:155–166.
47.
Hughes C, Gomez-Caminero A, Benkendorf J, Kerner J, Isaacs C, Barter J, Lerman C: Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns 1997;32:51–62.
48.
Lerman C, Croyle RT, Tercyak KP, Hamann H: Genetic testing: Psychological aspects and implications. J Consult Clin Psychol 2002;70:784–797.
49.
Donovan KA, Tucker DC: Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med 2000;23:15–36.
50.
Bottorff JL, Ratner PA, Balneaves LG, Richardson CG, McCullum M, Hack T, Chalmers K, Buxton J: Women’s interest in genetic testing for breast cancer risk: The influence of sociodemographics and knowledge. Cancer Epidemiol Biomarkers Prev 2002;11:89–95.
51.
Durfy SJ, Bowen DJ, McTiernan A, Sporleder J, Burke W: Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev 1999;8:369–375.
52.
Kinney AY, Choi YA, DeVellis B, Kobetz E, Millikan RC, Sandler RS: Interest in genetic testing among first-degree relatives of colorectal cancer patients. Am J Prev Med 2000;18:249–252.
53.
Ludman EJ, Curry SJ, Hoffman E, Taplin S: Women’s knowledge and attitudes about genetic testing for breast cancer susceptibility. Eff Clin Pract 1999;2:158–162.
54.
Andrykowski MA, Lightner R, Studts JL, Munn RK: Hereditary cancer risk notification and testing: How interested is the general population? J Clin Oncol 1997;15:2139–2148.
55.
National Center for Health Statistics (2002): Data File Documentation, National Health Interview Survey 2000 (machine readable data file and documentation). National Center for Health Statistics, Hyattsville, Maryland.
56.
Rogers EM: Diffusion of Innovations, ed 4. New York, Simon & Schuster, 1995, pp 161–203.
57.
Rakowski W, Assaf AR, Lefebvre RC, Lasater TM, Niknian M, Carleton RA: Information-seeking about health in a community sample of adults: Correlates and associations with other health-related practices. Health Educ Q 1990;17:379–393.
58.
Potosky AL, Breen N, Graubard BI, Parsons PE: The association between health care coverage and the use of cancer screening tests. Results from the 1992 National Health Interview Survey. Med Care 1998;36:257–270.
59.
Phillips KA, Kerlikowske K, Baker LC, Chang SW, Brown ML: Factors associated with women’s adherence to mammography screening guidelines. Health Serv Res 1998;33:29–53.
60.
Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R: Progress in cancer screening over a decade: Results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst 2001;93:1704–1713.
61.
Shah BV, Barnwell BG, Beiler GS: SUDAAN User’s Manual, Release 7.5. Research Triangle Park, Research Triangle Institute, 1997.
62.
Korn EL, Graubard BI: Analysis of Health Surveys. New York, Wiley, 2000, pp 128–129.
63.
Vishwanath K, Finnegan JR: The knowledge gap hypothesis: 25 years later. Communication Yearbook. Thousand Oaks, Sage Publications, 1996, pp 187–227.
64.
Tourangeau R, Rips IJ, Rasinski K: The Psychology of Survey Response. Cambridge, Cambridge University Press, 2000, vol 5, pp 257–258.
65.
Benjamin-Garner R, Oakes JM, Meischke H, Meshack A, Stone EJ, Zapka J, Finnegan JR Jr, Wallace L, Taylor J, McGovern P: Sociodemographic differences in exposure to health information. Ethn Dis 2002;12:124–134.
66.
Royak-Schaler R, deVellis BM, Sorenson JR, Wilson KR, Lannin DR, Emerson JA: Breast cancer in African-American families. Risk perception, cancer worry, and screening practices of first-degree relatives. Ann NY Acad Sci 1995;768:281–285.
67.
Audrain J, Lerman C, Rimer B, Cella D, Steffens R, Gomez-Caminero A: Awareness of heightened breast cancer risk among first-degree relatives of recently diagnosed breast cancer patients. The High Risk Breast Cancer Consortium. Cancer Epidemiol Biomarkers Prev 1995;4:561–565.
68.
Hughes C, Lerman C, Lustbader E: Ethnic differences in risk perception among women at increased risk for breast cancer. Breast Cancer Res Treat 1996;40:25–35.
69.
Johnson JD: Cancer-Related Information Seeking. Cresskill, Hampton Press, 1997.
70.
Johnson JD, Andrews JE, Allard S: A model for understanding and affecting cancer genetics information seeking. Lib Info Sci Res 2001;23:335–349.
71.
Freimuth V, Stein, JA, Kean, TJ: Searching for health information: The Cancer Information Service model. Philadelphia, University of Pennsylvania Press, 1989.
72.
Glanz K, Grove J, Le Marchand L, Gotay C: Underreporting of family history of colon cancer: Correlates and implications. Cancer Epidemiol Biomarkers Prev 1999;8:635–639.
73.
Kerber RA, Slattery ML: Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 1997;146:244–248.
74.
Brach C, Fraser I: Can cultural competency reduce racial and ethnic health disparities? A review and conceptual model. Med Care Res Rev 2000;57:(suppl 1):181–217.
75.
Ramirez AG: Consumer-provider communication research with special populations. Patient Educ Couns 2003;51–54.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.